by John Conrad | Aug 20, 2024 | NewsBrief
According to PitchBook’s latest Emerging Tech Research report on the medtech industry, the sector is showing resilience and growth despite recent market challenges. The report highlights the successful IPO of precision medicine company Tempus in June 2024 as a...
by John Conrad | Jul 17, 2024 | NewsBrief
Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, announced that its multimodal immune profile score (IPS) algorithmic test is now available for research use only (RUO). IPS is the first offering of a larger immunotherapy-based...
by John Conrad | Jun 27, 2024 | NewsBrief
Tempus AI, Inc. (NASDAQ: TEM) has achieved a significant milestone in the field of artificial intelligence and precision medicine. The company recently announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its innovative...
by John Conrad | Jun 14, 2024 | NewsBrief
Congratulations to iBIO member Tempus AI and its founder, Eric Lefkofsky, on their remarkable achievement! We are thrilled to announce that Tempus AI, a trailblazing precision-medicine startup, is set to make its highly anticipated debut on the stock market this...
by John Conrad | Jun 14, 2024 | iBIO News
From John: The news coverage of the BioPharma industry has been a study in contrasts. As I compile the daily NewsBrief, I come across numerous articles highlighting companies, both large and small, that are compelled to reduce their workforce due to insufficient...
